“Global Neurostimulation Devices market set to grow to $13bn by 2024” says new Visiongain report

28 November 2018
Pharma
Visiongain has launched a new pharma report Global Neurostimulation Devices Market 2019-2029: Spinal Cord Stimulators, Deep Brain Stimulators, Vagus Nerve Stimulators, Sacral Nerve Stimulators, Cortical Stimulators, Epilepsy, Pain Management, Hearing Loss, Incontinence, Gastroparesis, Parkinson’s Disease Neurostimulation is an advanced treatment which helps to reduce certain types of chronic pain. Neurostimulation works by intercepting pain signals before they reach the brain. are different types of neurostimulation devices available in the market, namely spinal cord stimulators, deep brain stimulators, vagus nerve stimulators, sacral nerve stimulators, and cortical stimulators among others. The lead analyst of the report commented "The leading medical device manufacturers are focusing on entering the emerging Asia-Pacific & Latin American countries to open manufacturing facility to capture the low-cost manufacturing advantage and to cater the significantly rising demand for medical devices from these regions. Thus, rising demand for medical devices from emerging markets is expected to create significant opportunities for global neurostimulation devices market vendors and the overall market." Leading companies featured in the report include Advanced Bionics, Boston Scientific Corporation, Cochlear ltd, Cyberonics, Medtronic, Neuronetics Inc, Nervo Corp., Cogentic Medical Inc, St Jude Medicall, NDI Medical Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100 About Visiongain Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever